Oral cancer drugs split into two very different Medicare billing paths in 2026, and the split confuses even experienced patients. Capecitabine, sold as Xeloda, belongs to a short statutory list of self-administered oral anticancer drugs that Medicare pays for under Part B rather than Part D, a carve-out created by Section 1861(s)(2)(Q) of the Social Security Act, added by the Balanced Budget Act of 1997, and codified in the Medicare Benefit Policy Manual, Chapter 15, Section 50.5.3. The rule exists because capecitabine is a prodrug of intravenous fluorouracil (5-FU), a drug that Part B has always covered when given by infusion. Congress decided that switching a patient from an IV chemotherapy drug to its oral form should not switch the patient from generous Part B coverage to a Part D formulary with tiers, deductibles, and prior authorization hurdles.
Capecitabine carries HCPCS code J8522, an unusual feature for an oral drug since J-codes almost always belong to injected or infused Part B products. The January 2026 Medicare Part B payment limit for J8522 is $0.08 per 50mg billing unit, so the total Part B allowed amount for a typical 21-day cycle (roughly 800 to 1,000 units depending on body surface area dosing) lands around $65 to $80 before the beneficiary's 20% coinsurance. That is dramatically cheaper than the $3,000 to $5,300 cash price for brand Xeloda, which is why almost every capecitabine prescription in 2026 gets filled with the generic. Genentech's brand Xeloda still appears on hospital bills and on cash-pay claims for patients whose pharmacy substitutes the brand by mistake or whose insurer requires the brand for a documented clinical reason.
Imbruvica (ibrutinib), Revlimid (lenalidomide), Ibrance (palbociclib), Xtandi (enzalutamide), and Jakafi (ruxolitinib) sit on the other side of the line. None of them is the oral form of a Part B-covered IV drug, so Medicare places all of them under Part D. Ibrutinib is one of the first 10 drugs negotiated under the Inflation Reduction Act, bringing its 2026 Medicare Maximum Fair Price to $9,319 per 30-day supply, a 38% cut from the pre-negotiation list price of $14,934. Part D patients taking any of these five drugs benefit from the 2026 annual out-of-pocket cap of $2,100, meaning a patient on Imbruvica typically reaches the cap within the first one or two fills of the year and pays $0 for the rest of their Part D drugs after that.
What Oral Cancer Drugs Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same oral cancer drugs can cost many times more at a hospital than at your local pharmacy:
2026 Oral Cancer Drugs Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Medicare Part B ASP rate (capecitabine, J8522) | $0.08/unit; ~$65-$80/cycle allowed amount before coinsurance | You pay 20% coinsurance after the 2026 Part B deductible of $283 |
| Pharmacy counter, retail cash (generic capecitabine) | $50 - $400/21-day cycle | Price varies widely by pharmacy; GoodRx coupon usually brings it to the low end |
| Pharmacy counter, retail cash (brand Xeloda) | $3,000 - $5,300/21-day cycle | Rarely dispensed once the generic is available; brand still billed at some hospitals |
| Medicare Part D (for Part D oral oncology drugs, e.g. Imbruvica) | Formulary tier copay/coinsurance, capped at $2,100/year | Applies to drugs not on the Part B oral anticancer list, like Imbruvica and Revlimid |
| Medicaid | $1 - $4/prescription, prior authorization common | Covers both Part B-style and Part D-style oral oncology drugs depending on state rules |
Part B ASP rate for J8522 reflects the January 2026 CMS quarterly pricing file. Retail cash prices reflect 2026 GoodRx and pharmacy survey data. Part D figures depend on your plan's formulary tier.
Source: CMS Medicare Part B ASP Drug Pricing Files (January 2026), Noridian LCD L33826, GoodRx, CMS IRA negotiated price fact sheet
Why Hospitals Charge So Much
Hospitals dispensing oral cancer drugs during an inpatient stay generally bundle the drug cost into the facility's Diagnosis Related Group (DRG) payment rather than billing it separately by NDC or J-code the way an outpatient specialty pharmacy would. When capecitabine or another oral oncology agent shows up as a distinct line item on an itemized inpatient bill, the hospital has usually applied its own chargemaster markup on top of its acquisition cost, and that markup is not tied to the Medicare Part B ASP rate of $0.08 per unit that applies outside the hospital.
Brand-name Xeloda charges above $5,300 per 21-day cycle on a hospital bill are a common dispute target, especially when the patient's outpatient pharmacy record shows generic capecitabine was dispensed for every other cycle. Request an itemized bill with the National Drug Code (NDC) for any oral chemotherapy line item, and compare it against the generic capecitabine retail range of $50 to $400 per cycle. A facility charging brand pricing for a generic drug, or charging the drug separately when it should be bundled into the DRG payment, is worth escalating to the hospital's patient financial services office.
Part D oral oncology drugs like Imbruvica and Revlimid follow a different inpatient pattern because their high five-figure monthly list prices make hospitals reluctant to stock them for inpatient use; most hospitals arrange for the patient's outpatient specialty pharmacy to continue supplying the drug even during a short inpatient stay. If one of these Part D drugs does appear on an inpatient bill, ask specifically whether it was billed against the DRG or as a separate pharmacy charge, since a separate charge on top of the DRG payment is a frequent coding error worth appealing.
HCPCS J-Codes: What Appears on Your Bill
Capecitabine is one of the rare oral drugs with a HCPCS Level II J-code because Medicare Part B, not Part D, pays for it under the self-administered oral anticancer drug benefit. Suppliers must be enrolled DME MAC suppliers and hold a signed order before billing.
HCPCS J-codes for Oral Cancer Drugs| Code | Description | What to look for |
|---|
| J8522 | Capecitabine, oral, 50mg billing unit | Check the unit count against your prescribed dose; billing units are per 50mg, not per tablet, and the wrong crosswalk can inflate or shrink your coinsurance |
HCPCS code J8520/J8521 (150mg and 500mg unit codes) were retired effective October 1, 2024, and replaced by the single J8522 (50mg unit) code implemented January 1, 2025, and still in effect for 2026.
Source: Noridian DME MAC LCD L33826 and Policy Article A52479, CMS HCPCS 2026 code file
Patient Assistance Programs
Genentech, the manufacturer of Xeloda, runs two separate programs depending on your insurance status, and independent foundations fill the gap for Medicare and Medicaid patients who cannot use manufacturer copay assistance. Patients on the Part D drugs discussed on this page (Imbruvica, Revlimid, Ibrance, Xtandi, Jakafi) should check that manufacturer's own PAP directly, since each is run separately (AbbVie for Imbruvica, Bristol Myers Squibb for Revlimid, Pfizer for Ibrance and Xtandi, Incyte for Jakafi).
Patient assistance programs for Oral Cancer Drugs| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Genentech Patient Foundation | Free brand Xeloda for uninsured or underinsured patients earning under roughly 500% FPL (about $150,000/year for a typical household) | gene.com/patients/patient-foundation |
| Genentech Oncology Co-pay Assistance Program | As low as $5/prescription for commercially insured patients, up to $25,000/year per product | copayassistancenow.com |
| CancerCare Co-Payment Assistance Foundation | $4,000 initial grant (up to $10,000/case) toward oral or IV chemotherapy copays for insured patients, including Medicare, under 400% FPL | cancercare.org/copayfoundation |
| PAN Foundation | Grants for Medicare and underinsured cancer patients across multiple disease funds | panfoundation.org |
Federal anti-kickback law (42 U.S.C. Section 1320a-7b) bars manufacturer coupons and copay cards, including the Genentech Oncology Co-pay Assistance Program, from being used by Medicare, Medicaid, TRICARE, or VA beneficiaries. If you have government insurance, apply to the Genentech Patient Foundation, CancerCare, or PAN Foundation instead.
Source: Genentech Patient Foundation, CopayAssistanceNow.com, CancerCare.org, PANFoundation.org, NeedyMeds.org
Medicare Part D
Medicare Part D applies to the majority of oral cancer drugs, including Imbruvica, Revlimid, Ibrance, Xtandi, and Jakafi, but not to capecitabine (which sits under Part B instead). For the Part D drugs, the 2026 annual out-of-pocket cap of $2,100 under the Inflation Reduction Act limits total spending across all covered Part D drugs combined in a calendar year. Because these drugs often list for $10,000 to $18,000 per month, most patients hit the $2,100 cap after their first fill and pay $0 for the remainder of the plan year on all their Part D prescriptions.
Formulary tier placement still matters before you hit the annual cap. Part D plans typically place high-cost oral oncology drugs on specialty tiers, which can carry coinsurance of 25% to 33% of the negotiated price for the first fill of the year, sometimes running into the thousands of dollars before the $2,100 cap kicks in. Starting in 2025, Medicare's Prescription Payment Plan lets beneficiaries spread that upfront cost evenly across the calendar year instead of paying it in one lump sum; ask your Part D plan to enroll you if a specialty-tier oral oncology drug creates a large first bill.
The Low Income Subsidy, also called Extra Help, reduces Part D cost-sharing to a nominal $0 to $13.55 copay per prescription in 2026 for qualifying beneficiaries with income below 150% of the federal poverty level. Extra Help applies to Part D oral oncology drugs like Imbruvica and Revlimid but does not change your Part B coinsurance for capecitabine, which stays at 20% after the deductible regardless of Extra Help status unless you also qualify for a Medicare Savings Program.
Common Oral Cancer Drugs Billing Errors
Oral oncology billing errors usually trace back to confusion over which part of Medicare should pay. Check for these issues before paying any bill above the ranges listed on this page:
- Capecitabine billed through a Part D prescription drug plan instead of Part B, which can trigger an incorrect formulary tier copay when it should be a flat 20% Part B coinsurance
- Pharmacy not enrolled as a DME MAC supplier attempting to bill Part B for capecitabine, resulting in an automatic denial that gets passed to the patient as a cash charge
- Retired HCPCS codes J8520 or J8521 still appearing on a 2026 claim instead of the current J8522 code, causing a claim rejection
- Brand Xeloda dispensed and billed at $3,000 to $5,300 per cycle when the prescription allowed generic substitution and generic capecitabine was in stock
- Part D specialty-tier coinsurance still being charged on Imbruvica, Revlimid, or another Part D oral oncology drug after the patient already crossed the $2,100 annual out-of-pocket cap
- Missing signed Standard Written Order on file, which invalidates a supplier's Part B claim for capecitabine and shifts the bill to the patient
Frequently Asked Questions
Why is capecitabine covered under Medicare Part B instead of Part D like most oral drugs?
Capecitabine (Xeloda) is a prodrug of intravenous fluorouracil, a chemotherapy drug that Medicare Part B has always covered when administered by infusion. Section 1861(s)(2)(Q) of the Social Security Act, added by the Balanced Budget Act of 1997, created a specific Part B benefit for self-administered oral anticancer drugs that are the oral form of, or a prodrug of, an IV chemotherapy drug already covered under Part B. Capecitabine, along with a short list of similar drugs, keeps its Part B coverage even though the patient takes it as a tablet at home rather than receiving an infusion in a clinic.
What does capecitabine cost without insurance in 2026?
Generic capecitabine costs $50 to $400 per 21-day treatment cycle at US retail pharmacies in 2026, depending on the pharmacy and any discount coupon applied. Brand-name Xeloda costs significantly more, running $3,000 to $5,300 for the same 21-day cycle. Because a generic version has been available since 2013, nearly all prescriptions in 2026 are filled with generic capecitabine rather than the brand.
Is there a generic or biosimilar for oral cancer drugs like Xeloda and Imbruvica?
Yes for capecitabine: generic capecitabine has been FDA-approved and on the market since 2013, cutting the cost from thousands of dollars per cycle to $50 to $400. Imbruvica (ibrutinib), Revlimid (lenalidomide), Ibrance (palbociclib), and Xtandi (enzalutamide) have no generic as of 2026 because their patents have not expired; expect generics starting between 2027 and 2032 depending on the drug. Small-molecule oral pills like these get generic competitors once patents expire, while infused biologic cancer drugs like trastuzumab or bevacizumab get biosimilars instead, a different regulatory pathway.
How do I apply for the Genentech Patient Foundation for Xeloda?
Visit gene.com/patients/patient-foundation or call 1-888-941-3331 (Monday through Friday, 6 a.m. to 5 p.m. Pacific) to start the application. You will need a valid Xeloda prescription, proof of household income, proof of US residency, and information about your current insurance status if you have any. Eligible uninsured patients earning under roughly 500% of the federal poverty level (about $150,000 per year for a typical household) receive Xeloda free of charge. If you have commercial insurance instead, ask about the separate Genentech Oncology Co-pay Assistance Program, which can lower your copay to $5.
Can I use a manufacturer coupon for Xeloda or Imbruvica if I have Medicare?
No. Federal anti-kickback law bars manufacturer coupons and copay cards, including the Genentech Oncology Co-pay Assistance Program and similar programs from AbbVie, Bristol Myers Squibb, and Pfizer, from being used by anyone with Medicare, Medicaid, TRICARE, or VA coverage. Medicare patients should instead apply to the manufacturer's income-based patient assistance program (like the Genentech Patient Foundation) or to an independent foundation such as CancerCare or the PAN Foundation, both of which explicitly serve Medicare beneficiaries.
What if my insurance denies coverage for an oral cancer drug?
Request the written denial notice and file a formal appeal within the deadline stated on it, usually 60 days for Medicare Part D and Part B claims. Ask your oncologist to request a peer-to-peer review with the plan's medical director and, for Part D specialty-tier denials, file a formulary exception request citing medical necessity. If the plan requires step therapy (trying a cheaper drug first), your prescriber can file a step-therapy override based on your specific cancer diagnosis and prior treatment history. If the appeal still fails, apply to the manufacturer's patient assistance program or an independent foundation while the appeal is pending.
Does the IRA negotiated Maximum Fair Price apply to oral cancer drugs?
Yes, for one so far: Imbruvica (ibrutinib) was among the first 10 drugs negotiated under the Inflation Reduction Act, and its Medicare Maximum Fair Price of $9,319 per 30-day supply took effect January 1, 2026, a 38% reduction from the prior list price of $14,934. Capecitabine was not selected for negotiation because it is already an inexpensive generic. Revlimid, Ibrance, Xtandi, and Jakafi have not been selected for negotiation as of 2026, though future negotiation rounds could add them; Medicare Part D patients on those drugs still benefit from the general $2,100 annual out-of-pocket cap regardless of negotiation status.
Do I qualify for the Genentech Patient Foundation if I have Medicare?
Yes. Medicare beneficiaries who cannot afford their Part B coinsurance or Part D cost-sharing for a Genentech oncology product, including Xeloda, can apply to the Genentech Patient Foundation. Because manufacturer copay cards are off-limits for government insurance, the foundation's income-based free-drug program is the correct pathway; income limits run to roughly 500% of the federal poverty level, and the foundation also considers regional cost of living and documented high medical expenses when reviewing borderline applications.
